Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksORPH.L Regulatory News (ORPH)

  • There is currently no data for ORPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - Open Orphan Plc

17 Dec 2019 16:38

RNS Number : 2214X
Crux Asset Management Limited
17 December 2019
 

FORM 8.3

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Full name of discloser:

CRUX Asset Management Limited

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Open Orphan plc

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

16/12/2019

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

N/A

 

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

Class of relevant security:

 

0.1p Ordinary

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

11,928,571

4.69

(2) Cash-settled derivatives:

 

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

 

TOTAL:

11,928,571

4.69

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b) Rights to subscribe for new securities (including directors' and other employee options)

 

Class of relevant security in relation to which subscription right exists:

Details, including nature of the rights concerned and relevant percentages:

 

 

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit

 

 

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

None

 

 

 

(c) Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

NO

 

 

Date of disclosure:

17/12/2019

Contact name:

Nino Baglione

Telephone number*:

0207 399 4633

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel's Market Surveillance Unit.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RETBLBDDSXBBGCR
Date   Source Headline
25th Oct 20227:00 amRNSChange of name to hVIVO plc effective
20th Oct 20227:00 amRNSCapital Markets Day
18th Oct 20227:00 amRNSCFO appointment & change of Board roles
30th Sep 20227:00 amRNSPositive in vitro results for FLU-v published
29th Sep 20229:30 amRNSDirector dealings
27th Sep 20227:00 amRNSUpcoming Scientific Presentations
15th Sep 20227:00 amRNSComment regarding press speculation
8th Sep 20227:01 amRNSInterim results and trading update
8th Sep 20227:00 amRNSIntention to change name to hVIVO plc
1st Sep 20227:20 amRNSCAP accreditation
25th Aug 20227:00 amRNSNotice of results
22nd Aug 20227:00 amRNS£10.4m contract with existing Big Pharma client
4th Aug 20227:00 amRNS£6.2m Influenza human challenge study contract
5th Jul 20221:17 pmRNSResult of AGM
30th Jun 20227:00 amRNSOmicron human challenge model
14th Jun 20227:00 amRNS£7.2m RSV human challenge study contract
10th Jun 202212:13 pmRNSBoard appointment amendment
10th Jun 202212:00 pmRNSAnnual Report and Notice of AGM
8th Jun 20227:00 amRNSBoard appointment
7th Jun 20229:05 amRNSSecond Price Monitoring Extn
7th Jun 20229:00 amRNSPrice Monitoring Extension
7th Jun 20227:00 amRNSFinal results
1st Jun 20227:00 amRNSGBP14.7m influenza contract signed
26th May 20227:00 amRNSCompletion of Nominated Adviser due diligence
24th May 20227:00 amRNSNotice of results
18th May 20227:00 amRNS£7.3m Influenza human challenge study contract win
12th May 20227:00 amRNSWellcome publication
5th May 20227:00 amRNSVaccine field study contract
4th May 20227:00 amRNSChallenge virus manufacturing contract
4th May 20227:00 amRNSComment re: speculation
28th Apr 20227:00 amRNSAppointment of Nominated Adviser and Joint Broker
13th Apr 20227:00 amRNSProposal to Distribution in Specie Shareholders
12th Apr 202212:00 pmRNSPresentation at World Vaccine Congress
6th Apr 20224:35 pmRNSPrice Monitoring Extension
6th Apr 20222:05 pmRNSSecond Price Monitoring Extn
6th Apr 20222:01 pmRNSPrice Monitoring Extension
6th Apr 202211:05 amRNSSecond Price Monitoring Extn
6th Apr 202211:00 amRNSPrice Monitoring Extension
31st Mar 202210:05 amRNSCharacterisation Study results in Nature Medicine
25th Mar 20227:00 amRNS£5m RSV human challenge study contract win
9th Mar 20224:41 pmRNSSecond Price Monitoring Extn
9th Mar 20224:37 pmRNSPrice Monitoring Extension
8th Mar 20227:00 amRNSTrading Update and screening facilities expansion
7th Mar 20222:06 pmRNSSecond Price Monitoring Extn
7th Mar 20222:00 pmRNSPrice Monitoring Extension
7th Mar 202211:06 amRNSSecond Price Monitoring Extn
7th Mar 202211:00 amRNSPrice Monitoring Extension
2nd Mar 20227:00 amRNSInvestor Presentations
24th Feb 20227:00 amRNSCEO Appointment
22nd Feb 20227:00 amRNSFDA Breakthrough Designation for Big Pharma RSV

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.